Related references
Note: Only part of the references are listed.Blockade of the IL-17 signaling pathway increased susceptibility of psoriasis patients to superficial fungal infections
Junichiro Hiruma et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2021)
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich et al.
LANCET (2021)
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Kenneth B Gordon et al.
LANCET (2021)
Bimekizumab versus Adalimumab in Plaque Psoriasis
R. B. Warren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
April Armstrong et al.
DERMATOLOGY AND THERAPY (2020)
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
Craig Leonardi et al.
DERMATOLOGY AND THERAPY (2020)
Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
Ralph Adams et al.
FRONTIERS IN IMMUNOLOGY (2020)
Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study
Alexander Egeberg et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry
Bruce Strober et al.
BMJ OPEN (2019)
Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report
Matthew K. Smith et al.
BMC GASTROENTEROLOGY (2019)
Suicidality among psoriasis patients: a critical evidence synthesis
Kevin K. Wu et al.
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA (2019)
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A. Deodhar et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Safety of biologics in psoriasis
Masahiro Kamata et al.
JOURNAL OF DERMATOLOGY (2018)
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Kim A. Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
Association of Psoriasis With Inflammatory Bowel Disease A Systematic Review and Meta-analysis
Yun Fu et al.
JAMA DERMATOLOGY (2018)
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
Sophie Glatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Treatment Approaches to Moderate to Severe Psoriasis
Paolo Gisondi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Psoriasis and comorbid diseases Epidemiology
Junko Takeshita et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis
April W. Armstrong et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2016)
Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study
A. Egeberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
Peter C. M. van de Kerkhof et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies
Andrew Blauvelt et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Robert E. Kalb et al.
JAMA DERMATOLOGY (2015)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Cutting Edge: IL-17-Secreting Innate Lymphoid Cells Are Essential for Host Defense against Fungal Infection
Andre Gladiator et al.
JOURNAL OF IMMUNOLOGY (2013)
The Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults
Kelly Posner et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Functional Specialization of Interleukin-17 Family Members
Yoichiro Iwakura et al.
IMMUNITY (2011)
Increased risk of infectious disease requiring hospitalization among patients with psoriasis: A population-based cohort
Marlies Wakkee et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Quality of life in patients with psoriasis
Monali J. Bhosle et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2006)
Share Paper
